Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Illumina, Inc. — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $43, while Illumina, Inc. trades at $191.33 (market cap $29.12B). The key difference: Illumina, Inc. is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.
| GPTY | ILMN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $205.10 |
52-Week Low | $34.73 | $91.00 |
Market Cap | — | $29.12B |
Enterprise Value | — | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
